|
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice
|
|
Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
|
|
Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia
|
|
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
|
|
Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences
|
|
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
|
|
Novel agents in the treatment of Waldenström's macroglobulinemia
|
|
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
|
|
Proteomic analysis of waldenstrom macroglobulinemia
|
|
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
|
